Skip to main content
SpringerLink
Log in

4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiatedin vitro

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

The effect of 4-hydroxytamoxifen (4OH-TAM), the potent anti-estrogenic metabolite of tamoxifen, on the radiosensitivity of MCF-7 cells irradiatedin vitro was determined. Radiation dose response curves were generated for MCF-7 cells maintained and irradiated in phenol red-free medium containing 10−10 M estradiol (E2) with or without 10−7 M 4OH-TAM. Immediately after irradiation cells were transferred to medium containing 10−10 M E2 supplemented with bovine serum to stimulate colony formation. Estradiol-stimulated cell proliferation was inhibited by 10−7 M 4OH-TAM, but radiation sensitivity was not significantly altered (p > 0.3). Continued incubation in the absence of E2 for an additional 24 hours after irradiation likewise failed to alter the radiosensitivity of 4OH-TAM-treated MCF-7 cells. These studies indicate that growth-inhibitory concentrations of the anti-estrogen 4OH-TAM do not modify thein vitro radiation sensitivity of this line of human breast carcinoma cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. The Nolvadex adjuvant trial organization: Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 57: 608–611, 1988

    Google Scholar 

  2. Stewart HJ: The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. J Natl Cancer Inst Monographs 11: 117–120, 1992

    Google Scholar 

  3. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1-15, 1992

  4. Cancer Research Campaign Breast Cancer Trials Group. The effect of adjuvant tamoxifen: The latest results from the Cancer Research Campaign Adjuvant Breast Trial. Eur J Cancer 28A: 904–907, 1992

    Google Scholar 

  5. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov N, Wolmark N, Wickerham D, Fisher E, Margolese R, Robidoux A, Shibata H, Terz J, Paterson A, Feldman M, Farrar W, Evans J, Lickley H, Ketner M: A randomized trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. N Engl J Med 320: 479–484, 1989

    Google Scholar 

  6. Osborne CK, Boldt DH, Estrada P: Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res 43: 1433–1439, 1984

    Google Scholar 

  7. Osborne CK, Boldt CH, Clark GM, Trent JM: Effects of tamoxifen on human breast cancer cell cycle kinetics: Accumulation of cells in early G1 phase. Cancer Res 43: 3583–3585, 1983

    Google Scholar 

  8. Lykkesfeldt AE, Larsen JK, Christensen IJ, Briand P: Effects of the antioestrogen tamoxifen on the cell cycle kinetics of the human breast cancer cell line, MCF-7. Br J Cancer 49: 717–722, 1984

    Google Scholar 

  9. Sarkaria JN, Gibson DFC, Jordan VC, Fowler JF, Lindstrom MJ, Mulcahy RT: Tamoxifen-induced increase in the potential doubling time (Tpot) of MCF-7 xenografts as determined by bromodeoxyuridine labeling and flow cytometry. Cancer Res 53: 4413–4417, 1993

    Google Scholar 

  10. Wazer DE, Tercilla OF, Lin PS, Schmidt-Ullrich R: Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17β-estradiol and tamoxifen. Br J Radiol 62: 1079–1083, 1989

    Google Scholar 

  11. Wazer DE, Joyce M, Chan W, Gewirtz D, Lin PS, Solares G, Schmidt-Ullrich RK: Effects of tamoxifen on the radiosensitivity of hormonally responsive and unresponsive breast carcinoma cells. Radiat Oncol Invest 1: 20–28, 1993

    Google Scholar 

  12. Jordan VC, Collins MM, Rowsby L, Prestwich G: A monohydroxylated metabolite of tamoxifen with potent antiestrogenic activity. J Endocrinol 75: 305–316, 1977

    Google Scholar 

  13. Soule HD, Vazquez J, Long A, Albert S, Brennan M: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409–1416, 1973

    Google Scholar 

  14. Jeng MH, Parker CJ, Jordan VC: Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 52: 6539–6546, 1992

    Google Scholar 

  15. LaBarca C, Paigen K: A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 102: 344–352, 1980

    Google Scholar 

  16. Lindstrom MJ, Kunugi KA, Kinsella TJ: Global comparison of radiation and chemotherapy dose-response curves with a test for interaction. Radiat Res 135: 269–277, 1993

    Google Scholar 

  17. Iliakis G: Radiation-induced potentially lethal damage: DNA lesions susceptible to fixation. Int J Radiat Biol 53: 541–584, 1988

    Google Scholar 

  18. Gould MN, Clifton KH: The survival of rat mammary gland cells following irradiationin vivo under different endocrinological conditions. Int J Radiat Oncol Biol Phys 4: 629–632, 1978

    Google Scholar 

  19. Brosing JW, Giese WL, Mulcahy RT: Lack of a differential radiation response for proliferative and non-proliferative rat thyroid cells (FRTL-5)in vitro. Int J Radiat Oncol Biol Phys 16: 1511–1517, 1989

    Google Scholar 

  20. Cormier EM, Jordan VC: Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor. Eur J Cancer Clin Oncol 25: 57–63, 1989

    Google Scholar 

  21. Wazer DE, Joyce M, Solares G, Schmidt-Ullrich R: Proliferative inhibition of human breast carcinoma cells by high concentration estradiol does not alter radiosensitivity. Breast Cancer Res Treat 18: 141–148, 1991

    Google Scholar 

  22. Mouridsen HT, Rose C, Overgaard M, Dombernowsky P, Panduro J, Thorpe S, Rasmussen BB, Blichert-Toft M, Anderson KW: Adjuvant treatment of postmenopausal patients with high risk primary breast cancer: Results from the Danish adjuvant trials DBCG 77 C and DBCG 82 C. Acta Oncologia 27: 699–705, 1988

    Google Scholar 

  23. Ryden S, Ferno M, Moller T, Aspegren K, Bergljung L, Killander D, Landberg T: Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial. Acta Oncologica 31: 271–274, 1992

    Google Scholar 

  24. Rutqvist LE, Cedermark B, Glas U, Johansson H, Rotstein S, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjalmar M: Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer. Cancer 66: 89–96, 1990

    Google Scholar 

  25. Kinsella TJ, Gould MN, Mulcahy RT, Ritter MA, Fowler JF: Keynote Address: Integration of cytostatic agents and radiation therapy: A different approach to ‘proliferating’ human tumors. Int J Radiat Oncol Biol Phys 20: 295–302, 1991

    Google Scholar 

  26. Rew DA, Campbell ID, Taylor I, Wilson GD: Proliferation indices of invasive breast carcinomas afterin vivo 5-bromo-2′-deoxyuridine labelling: a flow cytometric study of 75 tumors. Br J Surg 79: 335–339, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Human Oncology and the University of Wisconsin Comprehensive Cancer Center, University of Wisconsin, K4/338, 600 Highland Avenue, 53792, Madison, WI, USA

    Jann N. Sarkaria, Elizabeth M. Miller, Christopher J. Parker, V. Craig Jordan & R. Timothy Mulcahy

Authors
  1. Jann N. Sarkaria
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth M. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher J. Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Craig Jordan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Timothy Mulcahy
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sarkaria, J.N., Miller, E.M., Parker, C.J. et al. 4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiatedin vitro . Breast Cancer Res Tr 30, 159–165 (1994). https://doi.org/10.1007/BF00666060

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00666060

Key words

Search

Navigation